Key result
Implantation of a 2.25 mm bioresorbable-polymer sirolimus-eluting stent in very small coronary vessels resulted in a low 5-year major adverse cardiac event rate of 5.7% with no stent thrombosis.
Why the study?
Treatment of CAD in very small vessels is associated with an increased risk for cardiac events, prompting evaluation of the long-term safety and efficacy of a 2.25 mm bioresorbable-polymer sirolimus-eluting Ultimaster stent in Japanese patients.
Does a 2.25 mm bioresorbable-polymer sirolimus-eluting stent prevent cardiac events in Japanese patients with very small coronary artery disease?
Observational (n=70)
Yes
Does a 2.25 mm bioresorbable-polymer sirolimus-eluting stent prevent cardiac events in Japanese patients with very small coronary artery disease?
The 2.25 mm sirolimus-eluting stent demonstrated long-term safety and effectiveness for treating very small coronary artery disease, with a low 5-year MACE rate of 5.7% and no stent thrombosis.
Answers are grounded in this paper and cite their sources.
May support use in very small vessels; extends observational data but leaves open randomized comparisons.
The aim of this study is to evaluate the long-term safety and efficacy of the 2.25 mm bioresorbable-polymer sirolimus-eluting Ultimaster stent in a Japanese patient population. Treatment of coronary artery disease in very small vessels is associated with an increased risk for cardiac events. The CENTURY JSV study is a prospective, multicenter, single-arm study. Seventy patients with stable and unstable coronary artery disease with a coronary lesion eligible for implantation with a 2.25 mm stent were enrolled in this study. Patients underwent clinical follow-up through 5-year after the PCI procedure. The mean age was 70.4 ± 9.2 years. The prevalence of diabetes mellitus was 37.1%, all not insulin dependent. The incidence of major adverse cardiac events, defined as cardiac death, target vessel myocardial infarction (MI), and clinically driven target lesion revascularization (CD-TLR) at 5 years was 5.7%. A non-Q wave MI was noted in 1.4% and 4.3% underwent a CD-TLR. There was no stent thrombosis during the entire follow-up period. No cardiac events were reported between 2 and 5 years. This is the first study to demonstrate safety and effectiveness for 5 years after treatment of very small coronary disease with 2.25 mm-diameter DES.Clinical trial registration: UMIN000012928.
No takes yet. Share an insight, caveat, or question.
Shishido et al. (2022) conducted an observational in Very small coronary artery disease (n=70). 2.25 mm bioresorbable-polymer sirolimus-eluting Ultimaster stent was evaluated on Major adverse cardiac events (MACE) at 5 years. Implantation of a 2.25 mm bioresorbable-polymer sirolimus-eluting stent in very small coronary vessels resulted in a low 5-year major adverse cardiac event rate of 5.7% with no stent thrombosis.
Synapse has enriched 10 related papers. Consider them for comparative context: